Abstract

Large peritoneal macrophages (LPMs) play a role as gatekeepers of peritoneal homeostasis by providing a first line of defense against pathogens. A third of the LPMs express the surface receptor VSIG4, but it is unclear whether these cells differ from their VSIG4-negative counterparts and perform dedicated functions. We demonstrate that VSIG4+, but not VSIG4-, LPMs are in the majority derived from embryonal precursors, and their occurrence is largely independent of sex and microbiota but increases with age. Although their transcriptome and surface proteome are indistinguishable from VSIG4- LPMs at steady-state, VSIG4+ LPMs are superior in phagocytosing S. aureus bioparticles and colorectal carcinoma (CRC) cells. Anti-VSIG4 nanobody constructs that are ADCC-enabled allowed a selective elimination of the VSIG4+ LPM subset without affecting overall LPM abundance. This strategy uncovered a role for VSIG4+ LPMs in lowering the first peak of parasitemia in a Trypanosoma brucei brucei infection model and in reducing CRC outgrowth in the peritoneal cavity, a prime metastatic site in CRC patients. Altogether, our data uncover a protective role for VSIG4+ LPMs in infectious and oncological diseases in the peritoneal cavity.

Original languageEnglish
Article numbere202551804
Pages (from-to)1-10
Number of pages10
JournalEuropean Journal of Immunology
Volume55
Issue number5
DOIs
Publication statusPublished - May 2025

Bibliographical note

Publisher Copyright:
© 2025 The Author(s). European Journal of Immunology published by Wiley-VCH GmbH.

Keywords

  • Animals
  • Macrophages, Peritoneal/immunology
  • Mice
  • Humans
  • Peritoneal Cavity
  • Female
  • Male
  • Colorectal Neoplasms/immunology
  • Phagocytosis/immunology
  • Trypanosoma brucei brucei/immunology
  • Mice, Inbred C57BL
  • Staphylococcus aureus/immunology
  • Cell Line, Tumor
  • Neoplasm Metastasis
  • Single-Domain Antibodies/immunology

Cite this